Copyright © 2012 Iván Carrera et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. R. Cacabelos, L. Fernandez-Novoa, V. Lombardi, Y. Kubota, and M. Takeda, “Molecular genetics of Alzheimer's disease and aging,” Methods and Findings in Experimental and Clinical Pharmacology, vol. 27, pp. 1–573, 2005. View at Scopus
2. D. J. Selkoe, “Toward a comprehensive theory for Alzheimer's disease. Hypothesis: alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid β-protein,” Annals of the New York Academy of Sciences, vol. 924, pp. 17–25, 2000. View at Scopus
3. K. Blennow, M. J. de Leon, and H. Zetterberg, “Alzheimer's disease,” The Lancet, vol. 368, no. 9533, pp. 387–403, 2006. View at Publisher · View at Google Scholar · View at Scopus
4. A. Nunomura, T. Hofer, P. I. Moreira, R. J. Castellani, M. A. Smith, and G. Perry, “RNA oxidation in Alzheimer disease and related neurodegenerative disorders,” Acta Neuropathologica, vol. 118, no. 1, pp. 151–166, 2009. View at Publisher · View at Google Scholar · View at Scopus
5. D. J. Selkoe, “Toward a remembrance of things past: deciphering Alzheimer disease,” Harvey lectures, vol. 99, pp. 23–45, 2003. View at Scopus
6. R. Cacabelos, “Pharmacogenomics in alzheimer's disease,” Methods in Molecular Biology, vol. 448, pp. 213–357, 2008. View at Publisher · View at Google Scholar · View at Scopus
7. D. Schenk, R. Barbour, W. Dunn et al., “Immunization with amyloid-β attenuates Alzheimer disease-like pathology in the PDAPP mouse,” Nature, vol. 400, no. 6740, pp. 173–177, 1999. View at Publisher · View at Google Scholar · View at Scopus
8. F. Bard, R. Barbour, C. Cannon et al., “Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 4, pp. 2023–2028, 2003. View at Publisher · View at Google Scholar · View at Scopus
9. N. C. Carty, D. M. Wilcock, A. Rosenthal et al., “Intracranial administration of deglycosylated C-terminal-specific anti-Aβ antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice,” Journal of Neuroinflammation, vol. 3, article 11, 2006. View at Publisher · View at Google Scholar · View at Scopus
10. D. Morgan, “Immunotherapy for Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 9, supplement 3, pp. 425–432, 2006. View at Scopus
11. G. Mamikonyan, M. Necula, M. Mkrtichyan et al., “Anti-Aβ1-11 antibody binds to different β-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers,” The Journal of Biological Chemistry, vol. 282, no. 31, pp. 22376–22386, 2007. View at Publisher · View at Google Scholar · View at Scopus
12. C. A. Lemere and E. Masliah, “Can Alzheimer disease be prevented by amyloid-beta immunotherapy?” Nature Reviews Neurology, vol. 6, no. 2, pp. 108–119, 2010. View at Publisher · View at Google Scholar · View at Scopus
13. D. Schenk, “Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning,” Nature Reviews Neuroscience, vol. 3, no. 10, pp. 824–828, 2002. View at Publisher · View at Google Scholar · View at Scopus
14. D. Morgan, “Modulation of microglial activation state following passive immunization in amyloid depositing transgenic mice,” Neurochemistry International, vol. 49, no. 2, pp. 190–194, 2006. View at Publisher · View at Google Scholar · View at Scopus
15. G. Chen, K. S. Chen, D. Kobayashi et al., “Active β-amyloid immunization restores spatial learning in PDAPP mice displaying very low levels of β-amyloid,” Journal of Neuroscience, vol. 27, no. 10, pp. 2654–2662, 2007. View at Publisher · View at Google Scholar · View at Scopus
16. D. M. Wilcock, N. Gharkholonarehe, W. E. Van Nostrand, J. Davis, M. P. Vitek, and C. A. Colton, “Amyloid reduction by amyloid-β vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease,” Journal of Neuroscience, vol. 29, no. 25, pp. 7957–7965, 2009. View at Publisher · View at Google Scholar · View at Scopus
17. H. J. Fu, B. Liu, J. L. Frost, and C. A. Lemere, “Amyloid-β immunotherapy for Alzheimer's disease,” CNS and Neurological Disorders Drug Targets, vol. 9, no. 2, pp. 197–206, 2010. View at Scopus
18. M. Maier, T. J. Seabrook, N. D. Lazo et al., “Short amyloid-β (Aβ) immunogens reduce cerebral Aβ load and learning deficits in an Alzheimer's disease mouse model in the absence of an Aβ-specific cellular immune response,” Journal of Neuroscience, vol. 26, no. 18, pp. 4717–4728, 2006. View at Publisher · View at Google Scholar · View at Scopus
19. J. C. Dodart, K. R. Bales, K. S. Gannon et al., “Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model,” Nature Neuroscience, vol. 5, no. 5, pp. 452–457, 2002. View at Publisher · View at Google Scholar · View at Scopus
20. L. A. Kotilinek, B. Bacskai, M. Westerman et al., “Reversible memory loss in a mouse transgenic model of Alzheimer's disease,” Journal of Neuroscience, vol. 22, no. 15, pp. 6331–6335, 2002. View at Scopus
21. J. M. Orgogozo, S. Gilman, J. F. Dartigues et al., “Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization,” Neurology, vol. 61, no. 1, pp. 46–54, 2003. View at Scopus
22. J. A. R. Nicolll, D. Wilkinson, C. Holmes, P. Steart, H. Markham, and R. O. Weller, “Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report,” Nature Medicine, vol. 9, no. 4, pp. 448–452, 2003. View at Publisher · View at Google Scholar · View at Scopus
23. I. Ferrer, M. Boada Rovira, M. L. Sánchez Guerra, M. J. Rey, and F. Costa-Jussá, “Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer’s disease,” Brain Pathology, vol. 14, no. 1, pp. 11–20, 2004. View at Scopus
24. S. Gilman, M. Koller, R. S. Black et al., “Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial,” Neurology, vol. 64, no. 9, pp. 1553–1562, 2005. View at Publisher · View at Google Scholar · View at Scopus
25. E. Masliah, L. Hansen, A. Adame et al., “Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease,” Neurology, vol. 64, no. 1, pp. 129–131, 2005. View at Scopus
26. D. R. Howlett, “APP transgenic mice and their application to drug discovery,” Histology and Histopathology, vol. 26, no. 12, pp. 1611–1632, 2011. View at Scopus
27. K. H. Ashe and K. R. Zahs, “Probing the biology of Alzheimer's disease in mice,” Neuron, vol. 66, no. 5, pp. 631–645, 2010. View at Publisher · View at Google Scholar · View at Scopus
28. D. Games, D. Adams, R. Alessandrini et al., “Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein,” Nature, vol. 373, no. 6514, pp. 523–527, 1995. View at Scopus
29. K. Hsiao, P. Chapman, S. Nilsen et al., “Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice,” Science, vol. 274, no. 5284, pp. 99–102, 1996. View at Publisher · View at Google Scholar · View at Scopus
30. C. Sturchler-Pierrat, D. Abramowski, M. Duke et al., “Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 24, pp. 13287–13292, 1997. View at Publisher · View at Google Scholar · View at Scopus
31. T. Mustafiz, E. Portelius, M. K. Gustavsson et al., “Characterization of the brain β-amyloid isoform pattern at different ages of Tg2576 mice,” Neurodegenerative Diseases, vol. 8, no. 5, pp. 352–363, 2011. View at Publisher · View at Google Scholar · View at Scopus
32. E. McGowan, S. Sanders, T. Iwatsubo et al., “Amyloid phenotype characterization of transgenic mice overexpressing both mutant amyloid precursor protein and mutant presenilin 1 transgenes,” Neurobiology of Disease, vol. 6, no. 4, pp. 231–244, 1999. View at Publisher · View at Google Scholar · View at Scopus
33. L. Holcomb, M. N. Gordon, E. Mcgowan et al., “Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes,” Nature Medicine, vol. 4, no. 1, pp. 97–100, 1998. View at Publisher · View at Google Scholar · View at Scopus
34. M. A. Chishti, D. S. Yang, C. Janus et al., “Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695,” The Journal of Biological Chemistry, vol. 276, no. 24, pp. 21562–21570, 2001. View at Publisher · View at Google Scholar · View at Scopus
35. M. N. Gordon, L. A. Holcomb, P. T. Jantzen et al., “Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse,” Experimental Neurology, vol. 173, no. 2, pp. 183–195, 2002. View at Publisher · View at Google Scholar · View at Scopus
36. J. L. Jankowsky, D. J. Fadale, J. Anderson et al., “Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase,” Human Molecular Genetics, vol. 13, no. 2, pp. 159–170, 2004. View at Publisher · View at Google Scholar · View at Scopus
37. F. Trinchese, S. Liu, F. Battaglia, S. Walter, P. M. Mathews, and O. Arancio, “Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice,” Annals of Neurology, vol. 55, no. 6, pp. 801–814, 2004. View at Publisher · View at Google Scholar · View at Scopus
38. T. Malm, J. Koistinaho, and K. Kanninen, “Utilization of APPswe/PS1dE9 transgenic mice in research of Alzheimer's disease: focus on gene therapy and cell-based therapy applications,” International Journal of Alzheimer's Disease, vol. 2011, Article ID 517160, 8 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
39. M. Maceyka, K. B. Harikumar, S. Milstien, and S. Spiegel, “Sphingosine-1-phosphate signaling and its role in disease,” Trends in Cell Biology, vol. 22, no. 1, pp. 50–60, 2012. View at Scopus
40. S. Y. Guénette, “Mechanisms of Aβ clearance and catabolism,” NeuroMolecular Medicine, vol. 4, no. 3, pp. 147–160, 2003. View at Publisher · View at Google Scholar · View at Scopus
41. N. Andreasen, M. Sjögren, and K. Blennow, “CSF markers for Alzheimer's disease: total tau, phospho-tau and Aβ42,” World Journal of Biological Psychiatry, vol. 4, no. 4, pp. 147–155, 2003. View at Publisher · View at Google Scholar · View at Scopus
42. Z. Suo, A. A. Cox, N. Bartelli et al., “GRK5 deficiency leads to early Alzheimer-like pathology and working memory impairment,” Neurobiology of Aging, vol. 28, no. 12, pp. 1873–1888, 2007. View at Publisher · View at Google Scholar · View at Scopus
43. A. Sun, X. V. Nguyen, and G. Bing, “Comparative analysis of an improved thioflavin-S stain, Gallyas silver stain, and immunohistochemistry for neurofibrillary tangle demonstration on the same sections,” Journal of Histochemistry and Cytochemistry, vol. 50, no. 4, pp. 463–472, 2002. View at Scopus
44. T. Bussière, F. Bard, R. Barbour et al., “Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Aβ immunotherapy on their clearance,” American Journal of Pathology, vol. 165, no. 3, pp. 987–995, 2004. View at Scopus
45. J. Zhou, M. I. Fonseca, R. Kayed et al., “Novel Aß peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's disease,” Journal of Neuroinflammation, vol. 2, article 28, 2005. View at Publisher · View at Google Scholar · View at Scopus
46. M. Jones, J. L. Cordell, A. D. Beyers, A. G. D. Tse, and D. Y. Mason, “Detection of T and B cells in many animal species using cross-reactive anti-peptide antibodies,” Journal of Immunology, vol. 150, no. 12, pp. 5429–5435, 1993. View at Scopus
47. A. C. Allison, R. Cacabelos, V. R. M. Lombardi, X. A. Álvarez, and C. Vigo, “Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 25, no. 7, pp. 1341–1357, 2001. View at Publisher · View at Google Scholar · View at Scopus
48. W. Zhang, M. Narayanan, and R. M. Friedlander, “Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS,” Annals of Neurology, vol. 53, no. 2, pp. 267–270, 2003. View at Publisher · View at Google Scholar · View at Scopus
49. A. Muhs, D. T. Hickman, M. Pihlgren et al., “Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 23, pp. 9810–9815, 2007. View at Publisher · View at Google Scholar · View at Scopus
50. H. Le Stunff, S. Milstien, and S. Spiegel, “Generation and metabolism of bioactive sphingosine-1-phosphate,” Journal of Cellular Biochemistry, vol. 92, no. 5, pp. 882–899, 2004. View at Publisher · View at Google Scholar · View at Scopus
51. S. Pyne, J. S. Long, N. T. Ktistakis, and N. J. Pyne, “Lipid phosphate phosphatases and lipid phosphate signalling,” Biochemical Society Transactions, vol. 33, no. 6, pp. 1370–1374, 2005. View at Publisher · View at Google Scholar · View at Scopus
52. A. Pilorget, B. Annabi, F. Bouzeghrane, J. Marvaldi, J. Luis, and R. Béliveau, “Inhibition of angiogenic properties of brain endothelial cells by platelet-derived sphingosine-1-phosphate,” Journal of Cerebral Blood Flow and Metabolism, vol. 25, no. 9, pp. 1171–1182, 2005. View at Publisher · View at Google Scholar · View at Scopus
53. H. Rosen and E. J. Goetzl, “Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network,” Nature Reviews Immunology, vol. 5, no. 7, pp. 560–570, 2005. View at Publisher · View at Google Scholar · View at Scopus
54. S. E. Alvarez, S. Milstien, and S. Spiegel, “Autocrine and paracrine roles of sphingosine-1-phosphate,” Trends in Endocrinology and Metabolism, vol. 18, no. 8, pp. 300–307, 2007. View at Publisher · View at Google Scholar · View at Scopus
55. Y. Yatomi, “Sphingosine 1-phosphate in vascular biology: possible therapeutic strategies to control vascular diseases,” Current Pharmaceutical Design, vol. 12, no. 5, pp. 575–587, 2006. View at Publisher · View at Google Scholar · View at Scopus
56. T. Hla, “Signaling and biological actions of sphingosine 1-phosphate,” Pharmacological Research, vol. 47, no. 5, pp. 401–407, 2003. View at Publisher · View at Google Scholar · View at Scopus
57. T. Hla and V. Brinkmann, “Sphingosine 1-phosphate (S1P): physiology and the effects of S1P receptor modulation,” Neurology, vol. 76, no. 8, pp. S3–S8, 2011. View at Publisher · View at Google Scholar · View at Scopus
58. S. Spiegel and S. Milstien, “The outs and the ins of sphingosine-1-phosphate in immunity,” Nature Reviews Immunology, vol. 11, no. 6, pp. 403–415, 2011. View at Publisher · View at Google Scholar · View at Scopus
59. T. Kajimoto, T. Okada, H. Yu, S. K. Goparaju, S. Jahangeer, and S. I. Nakamura, “Involvement of sphingosine-1-phosphate in glutamate secretion in hippocampal neurons,” Molecular and Cellular Biology, vol. 27, no. 9, pp. 3429–3440, 2007. View at Publisher · View at Google Scholar · View at Scopus
60. V. Anelli, R. Bassi, G. Tettamanti, P. Viani, and L. Riboni, “Extracellular release of newly synthesized sphingosine-1-phosphate by cerebellar granule cells and astrocytes,” Journal of Neurochemistry, vol. 92, no. 5, pp. 1204–1215, 2005. View at Publisher · View at Google Scholar · View at Scopus
61. A. Kimura, T. Ohmori, R. Ohkawa et al., “Essential roles of sphingosine 1-phosphate/S1P1 receptor axis in the migration of neural stem cells toward a site of spinal cord injury,” Stem Cells, vol. 25, no. 1, pp. 115–124, 2007. View at Publisher · View at Google Scholar · View at Scopus
62. S. S. Lee, C. H. Woo, J. D. Chang, and J. H. Kim, “Roles of Rac and cytosolic phospholipase A2 in the intracellular signalling in response to titanium particles,” Cellular Signalling, vol. 15, no. 3, pp. 339–345, 2003. View at Publisher · View at Google Scholar · View at Scopus
63. C. Vigo-Pelfrey, D. Lee, P. Keim, I. Lieberburg, and D. B. Schenk, “Characterization of β-amyloid peptide from human cerebrospinal fluid,” Journal of Neurochemistry, vol. 61, no. 5, pp. 1965–1968, 1993. View at Publisher · View at Google Scholar · View at Scopus
64. L. Ruan, Z. Kang, G. Pei, and Y. Le, “Amyloid deposition and inflammation in APPswe/PS1dE9 mouse model of Alzheimer's disease,” Current Alzheimer Research, vol. 6, no. 6, pp. 531–540, 2009. View at Publisher · View at Google Scholar · View at Scopus
65. N. B. Chauhan, “Intracerebroventricular passive immunization with anti-oligoAβ antibody in TgCRND8,” Journal of Neuroscience Research, vol. 85, no. 2, pp. 451–463, 2007. View at Publisher · View at Google Scholar · View at Scopus
66. M. T. Heneka, H. Wiesinger, L. Dumitrescu-Ozimek, P. Riederer, D. L. Feinstein, and T. Klockgether, “Neuronal and glial coexpression of argininosuccinate synthetase and inducible nitric oxide synthase in Alzheimer disease,” Journal of Neuropathology and Experimental Neurology, vol. 60, no. 9, pp. 906–916, 2001. View at Scopus
67. M. Koistinaho, S. Lin, X. Wu et al., “Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-β peptides,” Nature Medicine, vol. 10, no. 7, pp. 719–726, 2004. View at Publisher · View at Google Scholar · View at Scopus
68. T. Wyss-Coray, J. D. Loike, T. C. Brionne et al., “Adult mouse astrocytes degrade amyloid-βin vitro and in situ,” Nature Medicine, vol. 9, no. 4, pp. 453–457, 2003. View at Publisher · View at Google Scholar · View at Scopus
69. R. Minkeviciene, J. Ihalainen, T. Malm et al., “Age-related decrease in stimulated glutamate release and vesicular glutamate transporters in APP/PS1 transgenic and wild-type mice,” Journal of Neurochemistry, vol. 105, no. 3, pp. 584–594, 2008. View at Publisher · View at Google Scholar · View at Scopus
70. P. Chakrabarty, A. Herring, C. Ceballos-Diaz, P. Das, and T. E. Golde, “Hippocampal expression of murine TNF results in attenuation of amyloid deposition in vivo,” Molecular Neurodegeneration, vol. 6, no. 1, article 16, 2011. View at Publisher · View at Google Scholar · View at Scopus
71. S. Shah and H. J. Federoff, “Therapeutic potential of vaccines for Alzheimers disease,” Immunotherapy, vol. 3, no. 2, pp. 287–298, 2011. View at Publisher · View at Google Scholar · View at Scopus
72. M. M. Racke, L. I. Boone, D. L. Hepburn et al., “Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid β,” Journal of Neuroscience, vol. 25, no. 3, pp. 629–636, 2005. View at Publisher · View at Google Scholar · View at Scopus
73. D. Boche, E. Zotova, R. O. Weller et al., “Consequence of Aβ immunization on the vasculature of human Alzheimer's disease brain,” Brain, vol. 131, no. 12, pp. 3299–3310, 2008. View at Publisher · View at Google Scholar · View at Scopus
74. A. Monsonego, J. Imitola, S. Petrovic et al., “Aβ-induced meningoencephalitis is IFN-γ-dependent and is associated with T cell-dependent clearance of Aβ in a mouse model of Alzheimer's disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 13, pp. 5048–5053, 2006. View at Publisher · View at Google Scholar · View at Scopus
75. H. L. Weiner and D. Frenkel, “Immunology and immunotherapy of Alzheimer's disease,” Nature Reviews Immunology, vol. 6, no. 5, pp. 404–416, 2006. View at Publisher · View at Google Scholar · View at Scopus
76. M. Kitazawa, S. Oddo, T. R. Yamasaki, K. N. Green, and F. M. LaFerla, “Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease,” Journal of Neuroscience, vol. 25, no. 39, pp. 8843–8853, 2005. View at Publisher · View at Google Scholar · View at Scopus
77. D. H. Cribbs, A. Ghochikyan, V. Vasilevko et al., “Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with β-amyloid,” International Immunology, vol. 15, no. 4, pp. 505–514, 2003. View at Publisher · View at Google Scholar · View at Scopus
78. V. Vasilevko, F. Xu, M. L. Previti, W. E. Van Nostrand, and D. H. Cribbs, “Experimental investigation of antibody-mediated clearance mechanisms of amyloid-β in CNS of Tg-SwDI transgenic mice,” Journal of Neuroscience, vol. 27, no. 49, pp. 13376–13383, 2007. View at Publisher · View at Google Scholar · View at Scopus
79. M. P. Lambert, A. K. Barlow, B. A. Chromy et al., “Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 11, pp. 6448–6453, 1998. View at Scopus
80. A. Boutajangout, D. Quartermain, and E. M. Sigurdsson, “Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model,” Journal of Neuroscience, vol. 30, no. 49, pp. 16559–16566, 2010. View at Publisher · View at Google Scholar · View at Scopus
81. R. B. DeMattos, K. R. Bales, D. J. Cummins, J. C. Dodart, S. M. Paul, and D. M. Holtzman, “Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 15, pp. 8850–8855, 2001. View at Publisher · View at Google Scholar · View at Scopus
82. P. Vollmar, J. S. Kullmann, B. Thilo et al., “Active immunization with amyloid-β 1-42 impairs memory performance through TLR2/4-dependent activation of the innate immune system,” Journal of Immunology, vol. 185, no. 10, pp. 6338–6347, 2010. View at Publisher · View at Google Scholar · View at Scopus
83. R. Cacabelos, “Pharmacogenomics in alzheimer's disease,” Methods in Molecular Biology, vol. 448, pp. 213–357, 2008. View at Publisher · View at Google Scholar · View at Scopus
84. R. Cacabelos, “Pharmacogenomics and therapeutic strategies for dementia,” Expert Review of Molecular Diagnostics, vol. 9, no. 6, pp. 567–611, 2009. View at Publisher · View at Google Scholar · View at Scopus